Everolimus fails to boost advanced NSCLC response
Phase II trial findings have ruled out a combination of erlotinib and everolimus for advanced non-small-cell lung cancer patients with progression after chemotherapy. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - January 28, 2014 Category: Cancer & Oncology Source Type: news
South Korean lung SCC genetic secrets revealed
Close examination of DNA taken from squamous cell carcinoma of the lung in South Korean patients has identified a gene fusion that may be targeted by current treatments, scientists say. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - January 27, 2014 Category: Cancer & Oncology Source Type: news
Sling technique boosts post-RARP early continence recovery
Researchers have shown that addition of the bladder neck sling suspension technique to robot-assisted radical prostatectomy can improve the early return of continence after surgery. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - January 27, 2014 Category: Cancer & Oncology Source Type: news
Novel HER2 mutation identified in familial lung adenocarcinomas
Researchers have identified a novel germline mutation in the transmembrane domain of the human epidermal growth factor receptor 2 gene in familial lung adenocarcinomas. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - January 24, 2014 Category: Cancer & Oncology Source Type: news
Immunotherapy maintenance shows promise in NSCLC
Results from a phase III trial have shown that tecemotide is no more effective than placebo as maintenance therapy in patients with non-small-cell lung cancer. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - January 24, 2014 Category: Cancer & Oncology Source Type: news
Etoposide plus cisplatin remains best for limited-stage SCLC
Etoposide plus cisplatin, given alongside accelerated hyperfractionated thoracic radiotherapy, remains the gold standard regimen for patients with limited-stage small-cell lung cancer, Japanese researchers say. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - January 23, 2014 Category: Cancer & Oncology Source Type: news
Overdiagnosis concerns raised for CT lung cancer screening
People participating in any future computed tomography lung cancer screening program would face a significant risk for overdiagnosis, US researchers caution in JAMA Internal Medicine. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - January 22, 2014 Category: Cancer & Oncology Source Type: news
Nomogram predicts overdiagnosis in prostate cancer screening
US researchers have developed a nomogram which they say can be used to predict whether prostate cancer has been overdiagnosed in individual patients diagnosed following prostate-specific antigen screening. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - January 20, 2014 Category: Cancer & Oncology Source Type: news
Call for long follow-up after CIN3 treatment
Researchers from Sweden say that women who have been treated for cervical precancer should receive lifelong follow-up, after finding that their risk for dying from vaginal or cervical cancer markedly increases after the age of 60 years. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - January 15, 2014 Category: Cancer & Oncology Source Type: news
Perioperative analgesia may improve prostate cancer outcomes
Neuraxial analgesia added to general anesthesia for radical retropubic prostatectomy may lead to improved oncologic outcomes in prostate cancer, US researchers have found. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - January 11, 2014 Category: Cancer & Oncology Source Type: news
Unexpected toxicity of pazopanib/pemetrexed in NSCLC halts study
A phase II study comparing first-line combination pazopanib/pemetrexed chemotherapy with the standard cisplatin/pemetrexed treatment in non-small-cell lung cancer was terminated early owing to an increased frequency of adverse events in the experimental arm. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - December 17, 2013 Category: Cancer & Oncology Source Type: news
Selenium fails to protect NSCLC patients against second primary tumors
Selenium supplementation does not reduce the risk for second primary tumors in patients with resected non–small-cell lung cancer, researchers say. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - December 17, 2013 Category: Cancer & Oncology Source Type: news
Erlotinib ‘dose-to-rash’ strategy effective in advanced NSCLC
Erlotinib as first-line therapy in patients with advanced non-small-cell lung cancer is equivalent to chemotherapy with regard to overall survival, an “all-comers” phase II trial has shown. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - December 16, 2013 Category: Cancer & Oncology Source Type: news
Chest wall resection effective for recurrent mesothelioma
Salvage chest wall resection could lengthen survival in patients with isolated chest wall recurrence of malignant pleural mesothelioma, research indicates. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - December 16, 2013 Category: Cancer & Oncology Source Type: news
Cetuximab fails in second-line combination for recurrent NSCLC
Results from a phase III trial indicate that cetuximab should not be given alongside chemotherapy in patients with recurrent non-small-cell lung cancer after platinum-based therapy. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - December 13, 2013 Category: Cancer & Oncology Source Type: news
